Novo Nordisk is a global pharmaceutical company and market leader in obesity and diabetes care, operating across approximately 80 countries and serving patients, healthcare professionals, and healthcare systems worldwide. The company manufactures and markets a broad portfolio of pharmaceutical products focused on three primary areas: obesity and diabetes care (including GLP-1 receptor agonists and insulins), rare diseases (particularly growth hormone and haemophilia treatments), and other therapeutic areas. Novo Nordisk generates revenue primarily through prescription drug sales, with products marketed through subsidiaries, distributors, and independent agents across major markets including the United States, Europe, Asia-Pacific, China, and emerging markets; pricing is subject to government regulation and negotiation with healthcare payers in most countries.